Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gastrointestinal tissue" refers to the collective tissues that make up the gastrointestinal tract, which includes the esophagus, stomach, small intestine, large intestine, and rectum. These tissues are organized into four main layers throughout the tract: • **Mucosa** – The innermost layer responsible for absorption and secretion; contains epithelial cells specialized for different functions depending on location[2][4][6]. • **Submucosa** – A connective tissue layer containing blood vessels, nerves, lymphatics; supports the mucosa[2][4]. • **Muscularis propria/externa** – Smooth muscle layers responsible for peristalsis and movement of contents through the GI tract[2][3][4]. • **Serosa/adventitia** – The outermost protective layer; serosa is present where organs are intraperitoneal while adventitia is found where they are retroperitoneal or attached to other structures[3][5]. The GI tissues perform essential roles in digestion by breaking down food mechanically and chemically with secreted enzymes/acids. They absorb nutrients via specialized epithelial surfaces with increased surface area from villi/microvilli in the small intestine. The mucosal immune system provides defense against pathogens. Alterations or diseases affecting these tissues can lead to conditions such as inflammatory bowel disease or cancers like colorectal carcinoma. Changes in extracellular matrix composition—such as increased collagen types—can serve as biomarkers for certain diseases within these tissues[1]. However, "gastrointestinal tissue" is not a specific molecular target such as a receptor or enzyme but rather an anatomical term describing multiple cell types and structures within an organ system. It cannot be directly targeted by drugs like a protein receptor could be. > "It is important to mention that ECM composition...differs according to the [GI] tissue...abnormal ECM remodeling contributes to progression of inflammatory bowel disease...increase of collagen-X...takes place in development of colorectal cancers..." [1] > "All segments of the GI tract are divided into four layers: mucosa...submucosa...muscularis propria...[and] serosa." [2] Because it does not refer to a single molecule or druggable entity but rather an entire class of complex multicellular structures/organs/tissues with diverse functions across many cell types, **this entry should be marked as incorrect if you require information about canonical drug targets such as receptors or enzymes.** If you need structured data on actual therapeutic targets within gastrointestinal tissues—such as "Glucagon-like peptide 1 receptor," "Histamine H2 receptor," etc.—please specify those molecules individually.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastrointestinal tissue.